Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin® in Children and Adults
Theodoros Papathanasiou, Henrik Agersø, Birgitte Bentz Damholt, Michael Højby Rasmussen, Rasmus Juul Kildemoes, Theodoros Papathanasiou, Henrik Agersø, Birgitte Bentz Damholt, Michael Højby Rasmussen, Rasmus Juul Kildemoes
Abstract
Background and objective: Once-daily injectable recombinant human growth hormone (GH) formulations (e.g. Norditropin®; Novo Nordisk A/S) are used to treat GH deficiency in children and adults, with much of the therapeutic effect mediated via the insulin-like growth factor-I (IGF-I) response. Despite a long history of use, there are few data on the pharmacokinetics and pharmacodynamics (serum IGF-I response) of this therapy, or of potential differences in the relationship of GH pharmacokinetic/pharmacodynamic (PK/PD) effects between children and adults. This study aimed to characterise the GH pharmacokinetics and IGF-I profile following daily subcutaneous GH in adults and children with GH deficiency.
Methods: A model was developed based on a population PK/PD modelling meta-analysis of data from three phase I clinical trials (two using Norditropin® as a comparator with somapacitan, and one as a comparator with a pegylated GH product). Sequential model building was performed, first developing a model that could describe GH pharmacokinetics. A PD model of IGF-I data was then developed using PK and PD data, and where all PK parameters were kept fixed to those estimated in the PK model.
Results: The model developed accurately describes and predicts GH pharmacokinetics and IGF-I response. Body weight was shown to have an important inversely correlated influence on GH exposure (and IGF-I standard deviation score), and this largely explained differences between adults and children.
Conclusions: The pharmacokinetics/pharmacodynamics developed here can inform expectations about the PD effects of different doses of GH in patients with GH deficiency of different body weights, regardless of their age.
Clinical trial registration: Pooled modelling analysis of data from ClinicalTrials.gov identifiers NCT01973244, NCT00936403 and NCT01706783.
Dates of registration: NCT01973244: 22 October, 2013; NCT00936403: 9 July, 2009; NCT01706783: 11 October, 2012.
Conflict of interest statement
Theodoros Papathanasiou and Birgitte Bentz Damholt were employees/shareholders of Novo Nordisk A/S at the time of writing. Henrik Agersø, Michael Højby Rasmussen and Rasmus Juul Kildemoes are employees/shareholders of Novo Nordisk A/S.
© 2021. The Author(s).
Figures
References
- Cuneo RC, Salomon F, McGauley GA, Sonksen PH. The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf) 1992;37(5):387–397. doi: 10.1111/j.1365-2265.1992.tb02347.x.
- Attanasio AF, Lamberts SW, Matranga AM, Birkett MA, Bates PC, Valk NK, et al. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J Clin Endocrinol Metab. 1997;82(1):82–8.
- Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr. 2016;86(6):361–397. doi: 10.1159/000452150.
- Raben MS. Growth hormone. 2. Clinical use of human growth hormone. N Engl J Med. 1962;266:82–6.
- Jorgensen JO, Pedersen SA, Thuesen L, Jorgensen J, Ingemann-Hansen T, Skakkebaek NE, et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet. 1989;1(8649):1221–1225. doi: 10.1016/S0140-6736(89)92328-3.
- Salomon F, Cuneo RC, Hesp R, Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med. 1989;321(26):1797–1803. doi: 10.1056/NEJM198912283212605.
- Elbornsson M, Gotherstrom G, Bosaeus I, Bengtsson BA, Johannsson G, Svensson J. Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol. 2013;168(5):745–753. doi: 10.1530/EJE-12-1083.
- Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717–797.
- Melmed S. Pathogenesis and diagnosis of growth hormone deficiency in adults. N Engl J Med. 2019;380(26):2551–2562. doi: 10.1056/NEJMra1817346.
- Jorgensen JO, Moller N, Lauritzen T, Christiansen JS. Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices. J Clin Endocrinol Metab. 1990;70(6):1616–1623. doi: 10.1210/jcem-70-6-1616.
- Laursen T, Gravholt CH, Heickendorff L, Drustrup J, Kappelgaard AM, Jørgensen JOL, et al. Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults. J Clin Endocrinol Metab. 2001;86(3):1222–1228.
- Wacharasindhu S, Aroonparkmongkol S, Srivuthana S. Measurement of IGF-1, IGFBP-3 and free IGF-1 levels by ELISA in growth hormone (GH) deficient children before and after GH replacement. Asian Pac J Allergy Immunol. 2002;20(3):155–160.
- Yuen KCJ, Biller BMK, Radovick S, Carmichael JD, Jasim S, Pantalone KM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr Pract. 2019;25(11):1191–1232. doi: 10.4158/GL-2019-0405.
- Jorgensen JO, Moller J, Moller N, Lauritzen T, Christiansen JS. Pharmacological aspects of growth hormone replacement therapy: route, frequency and timing of administration. Horm Res. 1990;33(Suppl. 4):77–82.
- Kearns GL, Kemp SF, Frindik JP. Single and multiple dose pharmacokinetics of methionyl growth hormone in children with idiopathic growth hormone deficiency. J Clin Endocrinol Metab. 1991;72(5):1148–1156. doi: 10.1210/jcem-72-5-1148.
- Walvoord EC, de la Peña A, Park S, Silverman BL, Cuttler L, Rose SR, et al. Inhaled growth hormone (GH) compared with subcutaneous GH in children with GH deficiency: pharmacokinetics, pharmacodynamics, and safety. J Clin Endocrinol Metab. 2009;94(6):2052–2059. doi: 10.1210/jc.2008-1897.
- Keller A, Wu Z, Kratzsch J, Keller E, Blum WF, Kniess A, et al. Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration. Eur J Endocrinol. 2007;156(6):647–653. doi: 10.1530/EJE-07-0057.
- Bidlingmaier M, Kim J, Savoy C, Kim MO, Ebrecht N, Motte S, et al. Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency. J Clin Endocrinol Metab. 2006;91:2926–2930. doi: 10.1210/jc.2006-0514.
- Battelino T, Rasmussen MH, De Schepper J, Zuckerman-Levin N, Gucev Z, Savendahl L. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: a randomized dose-escalation trial. Clin Endocrinol (Oxf) 2017;87(4):350–358. doi: 10.1111/cen.13409.
- de Schepper J, Rasmussen MH, Gucev Z, Eliakim A, Battelino T. Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics. Eur J Endocrinol. 2011;165(3):401–409. doi: 10.1530/EJE-11-0536.
- Rasmussen MH, Janukonyte J, Klose M, Marina D, Tanvig M, Nielsen LF, et al. Reversible albumin-binding GH possesses a potential once-weekly treatment profile in adult growth hormone deficiency. J Clin Endocrinol Metab. 2016;101(3):988–998. doi: 10.1210/jc.2015-1991.
- Fisher DM, Rosenfeld RG, Jaron-Mendelson M, Amitzi L, Koren R, Hart G. Pharmacokinetic and pharmacodynamic modeling of MOD-4023, a long-acting human growth hormone, in growth hormone deficiency children. Horm Res Paediatr. 2017;87(5):324–332. doi: 10.1159/000470842.
- Juul RV, Rasmussen MH, Agerso H, Overgaard RV. Pharmacokinetics and pharmacodynamics of once-weekly somapacitan in children and adults: supporting dosing rationales with a model-based analysis of three phase I trials. Clin Pharmacokinet. 2019;58(1):63–75. doi: 10.1007/s40262-018-0662-5.
- Bidlingmaier M, Friedrich N, Emeny RT, Spranger J, Wolthers OD, Roswall J, et al. Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab. 2014;99(5):1712–1721. doi: 10.1210/jc.2013-3059.
- Faria AC, Veldhuis JD, Thorner MO, Vance ML. Half-time of endogenous growth hormone (GH) disappearance in normal man after stimulation of GH secretion by GH-releasing hormone and suppression with somatostatin. J Clin Endocrinol Metab. 1989;68(3):535–541. doi: 10.1210/jcem-68-3-535.
- Hindmarsh PC, Matthews DR, Brain CE, Pringle PJ, di Silvio L, Kurtz AB, et al. The half-life of exogenous growth hormone after suppression of endogenous growth hormone secretion with somatostatin. Clin Endocrinol (Oxf) 1989;30(4):443–450. doi: 10.1111/j.1365-2265.1989.tb00444.x.
- ICH harmonized tripartite guideline guideline for good clinical practice. J Postgrad Med. 2001;47(1):45–50.
- World Medical Association Declaration of Helsinki ethical principles for medical research involving human subjects. J Int Bioethique. 2004;15(1):124–129. doi: 10.3917/jib.151.0124.
Source: PubMed